Related Experiment Video

Updated: Aug 6, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Treatment of adenovirus infections in the immunocompromised host

P Ljungman1

  • 1Department of Haematology, Karolinska University Hospital/Huddinge, 14186 Stockholm, Sweden. per.ljungman@medhs.ki.se

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|July 13, 2004
PubMed

Insights

Adenovirus infections pose a growing threat to immunocompromised patients. Current treatments show limited success, highlighting the need for novel therapeutic strategies and clinical trials.

Area of Science:

  • Infectious Diseases
  • Virology
  • Immunology

Background:

  • Adenovirus infections are increasingly recognized as significant causes of illness and death in severely immunocompromised individuals.
  • Existing antiviral drugs like ribavirin and cidofovir have demonstrated inconsistent efficacy in treating established adenovirus disease.
  • The management of adenovirus infections in this vulnerable population remains challenging, often with suboptimal therapeutic outcomes.

Purpose of the Study:

  • To review the current challenges in treating adenovirus infections in immunocompromised patients.
  • To evaluate the efficacy of existing antiviral therapies.
  • To propose and advocate for new therapeutic strategies and clinical investigations.

Main Methods:

  • Review of existing literature on adenovirus infections and treatments.
  • Analysis of case reports and small case series on antiviral drug efficacy.
  • Discussion of therapeutic limitations and future research directions.

Main Results:

  • Adenovirus infections are a rising cause of morbidity and mortality in severely immunocompromised patients.
  • Available antiviral agents (ribavirin, cidofovir) show limited and variable success.
  • Established adenovirus disease is difficult to treat, with therapy often yielding poor results.

Conclusions:

  • Novel therapeutic approaches are urgently needed for adenovirus infections in immunocompromised patients.
  • Prospective clinical trials are essential to evaluate new strategies, such as pre-emptive therapy.
  • Development of new antiviral agents and T-cell adoptive transfer therapies may offer improved treatment outcomes.

More Related Videos

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

An Efficient Method for Adenovirus Production10:06

An Efficient Method for Adenovirus Production

Published on: June 10, 2021

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...